🇺🇸 FDA
Pipeline program

First-in-Human Study of RO7812653

BP45770

Phase 1 other active

Quick answer

First-in-Human Study of RO7812653 for Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia) is a Phase 1 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)
Phase
Phase 1
Modality
other
Status
active

Clinical trials